BRISTOL MYERS SQUIBB
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)
Phase 3
Completed
- Conditions
- Chronic Kidney FailureKidney Transplantation
- Interventions
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2016-08-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 738
- Registration Number
- NCT00256750
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
🇺🇸Medical College Of Georgia, Augusta, Georgia, United States
Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 87
- Registration Number
- NCT00254293
- Locations
- 🇺🇸
Davita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸The Arthritis Clinic & Carolina Bone & Joint, Charlotte, North Carolina, United States
Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study
Phase 2
Completed
- Conditions
- Deep-Vein Thrombosis
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 520
- Registration Number
- NCT00252005
- Locations
- 🇸🇪
Local Institution, Vastervik, Sweden
A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control
Phase 3
Completed
- Conditions
- Diabetes, Type 2
- First Posted Date
- 2005-11-01
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 341
- Registration Number
- NCT00246987
- Locations
- 🇦🇺
Tasmania, Melbourne, Victoria, Australia
🇨🇳Local Institution, Taichung, Taiwan
Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia
Phase 2
Completed
- Conditions
- Dyslipidemia
- First Posted Date
- 2005-10-28
- Last Posted Date
- 2012-04-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 330
- Registration Number
- NCT00245388
- Locations
- 🇨🇦
Local Institution, Ottawa, Ontario, Canada
A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2010-09-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1159
- Registration Number
- NCT00240370
- Locations
- 🇵🇷
Local Institution, Ponce, Puerto Rico
Dose Ranging Study With LT, Monotherapy, PPAR
Phase 2
Completed
- Conditions
- Diabetes Mellitus II
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2010-09-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1260
- Registration Number
- NCT00240383
- Locations
- 🇬🇧
Local Institution, Glasgow, United Kingdom
MAD Refractory: Solid Tumor QD w/o Break
Phase 1
Completed
- Conditions
- HER2 or EGFR Expressing Advanced Solid Malignancies
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 45
- Registration Number
- NCT00207012
- Locations
- 🇪🇸
Local Institution, Barcelona, Spain
To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine
Phase 4
Completed
- Conditions
- AIDS
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-04-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 120
- Registration Number
- NCT00207168
Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)
Phase 4
Completed
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 252
- Registration Number
- NCT00207142
- Locations
- 🇬🇧
Local Institution, London, Greater London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath